133 related articles for article (PubMed ID: 34140559)
1. Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis.
Yoneshima Y; Iwama E; Matsumoto S; Matsubara T; Tagawa T; Ota K; Tanaka K; Takenoyama M; Okamoto T; Goto K; Mori M; Okamoto I
Sci Rep; 2021 Jun; 11(1):12732. PubMed ID: 34140559
[TBL] [Abstract][Full Text] [Related]
2. Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis.
Otsubo K; Iwama E; Ijichi K; Kubo N; Yoneshima Y; Inoue H; Tanaka K; Osoegawa A; Tagawa T; Nakanishi Y; Okamoto I
Cancer Sci; 2020 Jul; 111(7):2482-2487. PubMed ID: 32426915
[TBL] [Abstract][Full Text] [Related]
3. Genomic profiles of lung cancer associated with idiopathic pulmonary fibrosis.
Hwang JA; Kim D; Chun SM; Bae S; Song JS; Kim MY; Koo HJ; Song JW; Kim WS; Lee JC; Kim HR; Choi CM; Jang SJ
J Pathol; 2018 Jan; 244(1):25-35. PubMed ID: 28862766
[TBL] [Abstract][Full Text] [Related]
4. Common driver mutations and smoking history affect tumor mutation burden in lung adenocarcinoma.
Nagahashi M; Sato S; Yuza K; Shimada Y; Ichikawa H; Watanabe S; Takada K; Okamoto T; Okuda S; Lyle S; Takabe K; Tsuchida M; Wakai T
J Surg Res; 2018 Oct; 230():181-185. PubMed ID: 30072189
[TBL] [Abstract][Full Text] [Related]
5. Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis.
Takahashi T; Munakata M; Ohtsuka Y; Nisihara H; Nasuhara Y; Kamachi-Satoh A; Dosaka-Akita H; Homma Y; Kawakami Y
Cancer; 2002 Aug; 95(3):624-33. PubMed ID: 12209756
[TBL] [Abstract][Full Text] [Related]
6. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with
Offin M; Rizvi H; Tenet M; Ni A; Sanchez-Vega F; Li BT; Drilon A; Kris MG; Rudin CM; Schultz N; Arcila ME; Ladanyi M; Riely GJ; Yu H; Hellmann MD
Clin Cancer Res; 2019 Feb; 25(3):1063-1069. PubMed ID: 30045933
[TBL] [Abstract][Full Text] [Related]
7. Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses.
Guyard A; Danel C; Théou-Anton N; Debray MP; Gibault L; Mordant P; Castier Y; Crestani B; Zalcman G; Blons H; Cazes A
Respir Res; 2017 Jun; 18(1):120. PubMed ID: 28619094
[TBL] [Abstract][Full Text] [Related]
8. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer.
Wang Y; Kuan PJ; Xing C; Cronkhite JT; Torres F; Rosenblatt RL; DiMaio JM; Kinch LN; Grishin NV; Garcia CK
Am J Hum Genet; 2009 Jan; 84(1):52-9. PubMed ID: 19100526
[TBL] [Abstract][Full Text] [Related]
9. Postoperative morbidity, mortality, and survival in lung cancer associated with idiopathic pulmonary fibrosis.
Kawasaki H; Nagai K; Yoshida J; Nishimura M; Nishiwaki Y
J Surg Oncol; 2002 Sep; 81(1):33-7. PubMed ID: 12210025
[TBL] [Abstract][Full Text] [Related]
10. Decoding tumor mutation burden and driver mutations in early stage lung adenocarcinoma using CT-based radiomics signature.
Wang X; Kong C; Xu W; Yang S; Shi D; Zhang J; Du M; Wang S; Bai Y; Zhang T; Chen Z; Ma Z; Wang J; Dong G; Sun M; Yin R; Chen F
Thorac Cancer; 2019 Oct; 10(10):1904-1912. PubMed ID: 31414580
[TBL] [Abstract][Full Text] [Related]
11. Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis.
Aubry MC; Myers JL; Douglas WW; Tazelaar HD; Washington Stephens TL; Hartman TE; Deschamps C; Pankratz VS
Mayo Clin Proc; 2002 Aug; 77(8):763-70. PubMed ID: 12173712
[TBL] [Abstract][Full Text] [Related]
12. Genomic analysis between idiopathic pulmonary fibrosis and associated lung cancer using laser-assisted microdissection: A case report.
Iida Y; Gon Y; Nakanishi Y; Kurosawa Y; Nakagawa Y; Mizumura K; Shimizu T; Takahashi N; Masuda S
Thorac Cancer; 2021 May; 12(9):1449-1452. PubMed ID: 33784423
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary adenocarcinoma mutation profile in smokers with smoking-related interstitial fibrosis.
Primiani A; Dias-Santagata D; Iafrate AJ; Kradin RL
Int J Chron Obstruct Pulmon Dis; 2014; 9():525-31. PubMed ID: 24920890
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
Sabari JK; Leonardi GC; Shu CA; Umeton R; Montecalvo J; Ni A; Chen R; Dienstag J; Mrad C; Bergagnini I; Lai WV; Offin M; Arbour KC; Plodkowski AJ; Halpenny DF; Paik PK; Li BT; Riely GJ; Kris MG; Rudin CM; Sholl LM; Nishino M; Hellmann MD; Rekhtman N; Awad MM; Drilon A
Ann Oncol; 2018 Oct; 29(10):2085-2091. PubMed ID: 30165371
[TBL] [Abstract][Full Text] [Related]
15. Genetic alterations in squamous cell lung cancer associated with idiopathic pulmonary fibrosis.
Hata A; Nakajima T; Matsusaka K; Fukuyo M; Nakayama M; Morimoto J; Ito Y; Yamamoto T; Sakairi Y; Rahmutulla B; Ota S; Wada H; Suzuki H; Iwata T; Matsubara H; Ohara O; Yoshino I; Kaneda A
Int J Cancer; 2021 Jun; 148(12):3008-3018. PubMed ID: 33533494
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics of surgically resected lung cancer associated with idiopathic pulmonary fibrosis.
Kawasaki H; Nagai K; Yokose T; Yoshida J; Nishimura M; Takahashi K; Suzuki K; Kakinuma R; Nishiwaki Y
J Surg Oncol; 2001 Jan; 76(1):53-7. PubMed ID: 11223825
[TBL] [Abstract][Full Text] [Related]
17. Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.
Kazdal D; Endris V; Allgäuer M; Kriegsmann M; Leichsenring J; Volckmar AL; Harms A; Kirchner M; Kriegsmann K; Neumann O; Brandt R; Talla SB; Rempel E; Ploeger C; von Winterfeld M; Christopoulos P; Merino DM; Stewart M; Allen J; Bischoff H; Meister M; Muley T; Herth F; Penzel R; Warth A; Winter H; Fröhling S; Peters S; Swanton C; Thomas M; Schirmacher P; Budczies J; Stenzinger A
J Thorac Oncol; 2019 Nov; 14(11):1935-1947. PubMed ID: 31349062
[TBL] [Abstract][Full Text] [Related]
18. Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens.
Parikh K; Huether R; White K; Hoskinson D; Beaubier N; Dong H; Adjei AA; Mansfield AS
JAMA Netw Open; 2020 Feb; 3(2):e200202. PubMed ID: 32108894
[TBL] [Abstract][Full Text] [Related]
19. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
20. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer.
Mao X; Zhang Z; Zheng X; Xie F; Duan F; Jiang L; Chuai S; Han-Zhang H; Han B; Sun J
J Thorac Oncol; 2017 Apr; 12(4):663-672. PubMed ID: 28007624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
